Clinical trialPhase 1Active not recruiting
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-ADC in Participants With Advanced Cancer
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 2 February 2022
- Expected end
- 15 February 2027
- Enrollment
- 163 participants
- Sites
- 12
- Primary outcomes
- Incidence and severity of adverse events and serious adverse events; Maximum Tolerated Dose (MTD); Recommended Phase 2 Dose (RP2D)
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 13 January 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer